Dr. Rayford attended the University of Kansas where he received his doctorate (Ph.D.) in Biochemistry in 1987, and his Medical Degree in 1991. He completed general surgery training at St. Luke’s Hospital in Kansas City, MO, and urology training at the University of Kansas. Dr. Rayford completed a urologic oncology fellowship at the National Institutes of Health, National Cancer Institute in Bethesda, MD. He maintains certification by the American Board of Urology. Dr. Rayford has published extensively in the areas of prostate cancer, kidney cancer, benign prostate hypertrophy and health disparities. He is an Associate Professor in the Department of Preventive Medicine at the University of Tennessee, partner with The Urology Group of Memphis, TN, and Chief Executive Office for Q-Leap Health, Inc. and Transformative Development Corporation. He currently holds membership with the American Urology Association, American Association of Clinical Urologists, National Medical Association and R. Frank Jones Urological Society. He provides exceptional urological care to patients in Memphis, TN, and Southaven, MS.

Robert L Waterhouse Jr., MD MBA HSM attended Northwestern University for his undergraduate and medical school education. He completed urology training at Case Western University Hospitals of Cleveland for both residency and a fellowship in stone disease.  After finishing training, he initially followed an academic career path with the Urology Department at the Mount Sinai School of Medicine in New York.  There he became the director of Minimally Invasive Urologic Surgery and Stone Disease.  He elected to leave academic medicine in 1999 to start an independent practice of urology in the greater Charlotte metropolitan area.  He was the inaugural President and managing partner of his urology group through 2011, until the practice merged with other regional urology groups to form a largest urology group in the Carolinas. The larger group fostered the opportunity to become more involved in health care management as the Chief Medical Officer and clinical research, largely in the area of prostate cancer as the group’s research champion. He pursued additional management skills by attending Duke’s University Fuqua School of Business for an MBA and Health Sector Management, with completion in 2016. In 2017, he chose to broaden his pursuit of health care management through transitioning to a role in population health management with a health insurance company and currently works as a Lead Medical Director for Blue Cross of NC.

Dr. Pettaway is a Professor of Urology at The University of Texas MD Anderson Cancer Center in Houston, Texas. His clinical practice is based on treating patients with genitourinary malignancies, including penile, urethral, and prostate malignancies. The goal of his prostate-related studies is 1) to further define host and molecular markers of cancer progression, and 2) to reduce disparities in prostate cancer outcomes among African Americans and the underserved by studying both clinical and biologic correlates of aggressive disease. He has served as the Medical Director of the Prostate Outreach Project (POP), an initiative which has educated and screened over 5,000 men. Dr. Pettaway has also served as the Co-Director of a National Cancer Institute-funded study evaluating the influence of West African ancestry on the incidence and aggressiveness of prostate cancer among African American and Puerto Rican populations.

Randy V. Bradley, PhD, CPHIMS, FHIMSS is a preeminent thought leader with expertise in digital health, healthcare information technology (IT), digital transformation, and the strategic application of business analytics and IT. In addition to co-founding ConDUC, he is EVP, Digital Transformation in Life Sciences for Bio Supply Management Alliance (BSMA), co-founder and Chief Information Officer for Q-Leap Health, Inc., and Principal Owner of RV Bradley, LLC. Dr. Bradley holds a Ph.D. in Management of Information Technology and Innovation, an M.S. in Management Information Systems, and a B.S. in Computer Engineering, all from Auburn University. Dr. Bradley is a and highly sought-after speaker for professional and corporate conferences and events with 20+ years of industry experience as a consultant, IT strategist, and researcher, and is an Associate Professor of Supply Chain and Information Systems Management in the Haslam College of Business at The University of Tennessee.

Dr. Burnett is the Patrick C. Walsh Distinguished Professor of Urology and Professor, Oncology Center, at the Johns Hopkins University School of Medicine.  He is an accomplished urologic surgeon and scientist, recognized for diverse leadership and service roles in urologic healthcare, ranging across missions of research, education, clinical practice and advocacy.  Dr. Burnett specializes in sexual medicine, major pelvic reconstruction, voiding dysfunction, prostate cancer, and lower genitourinary tract malignancies.  He is considered the world-authority in the science and medicine of male sexual dysfunction, and among his many academic contributions he made original scientific discoveries that paved the way for the development of oral medications to treat erectile dysfunction and was the lead urologic surgeon in the first-ever penis and anterior pelvis transplant surgery.  He has written more than 350 original peer-review articles and 50 book chapters along with numerous additional editorials and publications related to his biomedical research and clinical activities.  He also founded and directs a non-profit humanitarian organization called UroMissionsWorks Incorporated.   He received his A.B. degree in Biology from Princeton University and M.D. and M.B.A. degrees from Johns Hopkins University.  He performed his post-graduate training in general surgery, urology and genitourinary reconstructive surgery at the Johns Hopkins Hospital and was awarded an American Foundation for Urologic Disease new investigator scholarship.  He is an alumni member of the Alpha Omega Alpha Honor Medical Society and Fellow of the American College of Surgeons.  Among various awards, Dr. Burnett received the Urology Care Foundation Distinguished Mentor Award in 2016, the Distinguished Contribution Award from the American Urological Association in 2018, and the Ferdinand C. Valentine Medal from The New York Academy of Medicine in 2020.

Dr. Nyame is a surgeon, researcher, educator, and patient advocate who specializes in urologic oncology and general urology. His clinical interests include open and minimally invasive kidney, prostate, bladder and testicular cancer surgeries. Dr. Nyame attended medical school at the Feinberg School of Medicine at Northwestern University and business school at the Kellogg School of Management at Northwestern University, graduating in 2012. Prior to medical school, he completed a master’s in health services and administration at the school of public health at the George Washington University. Dr. Nyame completed his general surgery internship and urology residency training at the Glickman Urological and Kidney Institute at the Cleveland Clinic. He came to the northwest to complete a Society of Urologic Oncology accredited fellowship at the University of Washington and joined the faculty upon the completion of his training. Dr. Nyame has a research interest in healthcare disparities in urologic cancers, with a focus in both the molecular epigenomic and health services aspects of health inequities in prostate cancer and other urologic malignancies.

Dr. Olorunseun Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, USA, and a PhD in molecular medicine from the University of East Anglia, Norwich, United Kingdom. He is the founding Director of the Hunter College Center for Cancer Health Disparities Research, tenured Associate Professor of Biological Sciences at Hunter College of The City University of New York, and a member of faculty in the Biology and Biochemistry PhD programs at The Graduate Center of The City University of New York. Dr. Ogunwobi is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with established racial disparities, such as prostate cancer. His laboratory has established novel circulating tumor cell models that are being used progressively to elucidate molecular mechanisms underlying the role of circulating tumor cells in cancer metastasis. A major focus of Dr. Ogunwobi’s laboratory are studies elucidating the role of non-coding RNAs derived from the PVT1 gene locus in the development and progression of solid organ cancers such as prostate cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi is a Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants (CA221704 and CA221705), Contact Principal Investigator of 3U54CA221704-03S1 and Co-Investigator on R01 grant CA239603 from the National Cancer Institute. An author of over 60 peer-reviewed journal articles and 2 book chapters, Dr. Ogunwobi has been issued 4 United States patents for biotechnology inventions with potential clinical applications in cancer, and he is a Co-Founder of NucleoBio, Inc, a City University of New York start-up biotechnology company.

Wendy Short Bartie is Vice President, Commercial Operations for the US Oncology Organization.  In her current role, Wendy is responsible for building the long-term strategic outlook and driving collaboration for the US sales, market access and key account organizations. Prior to joining the US Team, Wendy was the Associate Vice-President of Global Marketing for Genitourinary Cancers (GU), including renal cell carcinoma, prostate cancer and bladder cancer.   Wendy was responsible for developing Merck’s business strategy and ensuring the achievement of near-term business objectives for GU cancers. Wendy first joined Merck three years ago as the Global Marketing Lead for breast cancer within the Women’s Cancers tumor team and then was promoted to Executive Director and GDL for Women’s Cancers in 2017 where she led the expansion of the Women’s Cancer strategy and program.  Prior to joining Merck, Wendy held a range of commercial roles with increasing responsibility in sales, business analytics and marketing in cardiovascular, neuroscience, osteoporosis, lung cancer, supportive care and chronic myeloid leukemia at various companies including Novartis, Heron Therapeutics, Johnson and Johnson, Pharmacia and Abbott Labs. Prior to her career in pharma, Wendy was a Public Defender in Washington, DC and Bronx, New York. Wendy received her Bachelor of Arts from Clark Atlanta University and her Juris Doctor from Loyola University Chicago, School of Law. Wendy’s favorite hobbies include painting and reading. Wendy lives in West Orange, New Jersey with her husband and daughter, Jared and Madison.